FDA Broadens Vemlidy Indication for Pediatric Chronic HBV Treatment
Gilead Sciences, Inc. has announced the U.S. Food and Drug Administration’s (FDA) approval of the supplemental new drug application...
Gilead and Xilio Enter Exclusive License Agreement for Tumor-Activated IL-12 Program
Gilead Sciences, Inc. and Xilio Therapeutics, Inc. have entered into an exclusive license agreement to develop and commercialize XTX301,...
European Commission Approves Keytruda® Plus Chemotherapy for Resectable NSCLC
Merck announced that the European Commission (EC) has approved KEYTRUDA, its anti-PD-1 therapy, for use in combination with platinum-containing...
BMS’s KRYSAL-12 Trial Shows Promise for Krazati in KRASG12C-Mutated NSCLC
Bristol Myers Squibb has announced significant outcomes from its Phase 3 KRYSTAL-12 study, evaluating KRAZATI® (adagrasib) in patients with...
AN2 Therapeutics Resumes Phase 2/3 Trial for EBO-301
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to creating treatments for rare, chronic, and significant infectious diseases, announced...
SecondWave Systems Secures $3M Additional Financing to Advance Ultrasound-Based Anti-Inflammatory Therapy
SecondWave Systems, Inc., an innovative company at the forefront of bio-ultrasonic medicine development, is making significant strides in creating...
AI-Driven Pathology: A New Era of Precision Clinical Trials
PathAI emerges as an enterprise transforming clinical trials with groundbreaking precision in the dynamic field of AI-driven pathology. Ben...
Clinical Trial Complexity: A Unique Challenge Tackled
As clinical trial complexity continues to rise, effective technology is paramount. In this interview, we discussed clinical trial technology...
How Pfizer Uses AI to Transform Clinical Trial Data Oversight
At the 2024 SCOPE Summit, Demetris Zambas, VP and Global Head of Data Monitoring and Management at Pfizer explored...
Photopharmics Initiates Largest Phototherapy Trial for Parkinson’s Disease
PhotoPharmics, in partnership with the Center for Health + Technology (CHeT) at the University of Rochester Medical Center (URMC),...